列纳利多米德减轻心脏纤维化和由β-上腺素受体激活诱导的炎症
Ran Jiao1, Wenqi Li2, Xiaoting Gu1
1State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, College of Life Sciences, Nankai University, Tianjin 300353, China; Tianjin Key Laboratory of Molecular Drug Research, International Joint Academy of Biomedicine, Tianjin 300457, China.
International immunopharmacology
|May 18, 2025
概括
列纳利多米德 (Len) 可以缓解心脏纤维化和由过度β-上腺素受体 (β-AR) 激活引起的炎症. 这种药物向AKT1,影响PI3K/AKT,ERK和NF-κB信号通路.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 过度的β-上腺素受体 (β-AR) 激活与心血管疾病有关,导致心脏纤维化和炎症.
- 列纳利多米德 (Len) 在各种疾病中表现出抗纤维性质,但其在β-AR介导的心脏问题中的作用尚未完全理解.
研究的目的:
- 调查莱纳利多米德 (Len) 在缓解心脏纤维化和因β-AR过度激活引起的炎症方面的疗效.
- 阐明潜在的分子机制,包括信号通路和潜在的分子标.
主要方法:
- 用异二醇 (ISO) 治疗小鼠,以诱导β-AR过度激活,有或没有莱纳利多米德 (Len) 预处理.
- 心脏功能,纤维化和炎症在体内被评估.
- 心脏纤维细胞和巨细胞进行了体外治疗,以检查Len对细胞激活和炎症反应的影响.
- 分析了信号通路 (PI3K/AKT,ERK,NF-κB) 和基因表达.
- 进行KEGG丰富分析以确定分子标.
主要成果:
- 列纳利多米德 (Len) 在体内缓解β-AR诱导的心脏功能障碍和纤维化,由PI3K/AKT和ERK信号介导.
- 在体外通过PI3K/AKT和ERK通路减弱β-AR诱导的心脏纤维细胞激活.
- 伦抑制了β-AR诱导的心脏炎症和巨细胞在体内和体外的炎症性细胞因子表达,涉及PI3K/AKT和NF-κB信号传递.
- 在KEGG分析中,AKT1被确定为Len在心脏纤维细胞和巨细胞中的关键标.
结论:
- 列纳利多米德 (Len) 有效地改善心脏纤维化和由β-上腺刺激引起的炎症.
- 伦的保护机制涉及PI3K/AKT,ERK和NF-κB信号通路的调制.
- 伦通过向心脏细胞和巨细胞中的AKT1来发挥其治疗作用.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
347
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
347
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
394
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
394
01:22Heart Failure Drugs: β-Blockers
295
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
295
01:22Heart Failure Drugs: Diuretics
306
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
306
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
514
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
514
01:26Heart Failure Drugs: Inotropic Agents
469
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
469